


Financial results for the quarter and year ended 31 March 2016

Part I	Rs in lakhs (except for number of shares)					
Statement of audited results for the quarter and year ended 31 March 2016						
Sl No.	Particulars	3 months ended 31/03/2016 (Audited) ^a	3 months ended 31/12/2015 (Unaudited)	3 months ended 31/03/2015 (Audited)	Year ended 31/03/2016 (Audited) ^a	Previous year ended 31/03/2015 (Audited)
1	Income from operations					
	a) Net sales/ income from operations (net of excise duty)	13,351.48	14,456.08	12,080.37	52,645.98	46,904.88
	b) Other operating income ^{3,5}	2,530.56	2.13	4,774.66	3,727.25	4,802.06
	Total income from operations (net)	15,882.04	14,458.21	16,855.03	56,373.23	51,706.94
2	Expenses					
	(a) Cost of materials consumed	868.74	506.07	1,169.03	3,475.85	2,678.12
	(b) Purchase of stock-in-trade	4,821.39	4,628.61	1,776.85	15,888.71	16,727.75
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(521.24)	272.13	2,513.13	541.52	600.76
	(d) Employee benefits expense ⁵	5,086.01	3,881.28	3,659.79	16,934.52	15,984.04
	(e) Depreciation and amortisation expense	423.71	444.46	401.91	1,742.64	1,528.15
	(f) Selling, marketing and distribution ⁵	2,234.57	1,387.20	1,149.87	7,194.29	6,488.22
	(g) Other expenses ⁵	3,071.95	2,618.99	2,506.08	10,696.60	10,368.71
	Total expenses	15,985.13	13,738.74	13,176.66	56,474.13	54,375.75
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	(103.09)	719.47	3,678.37	(100.90)	(2,668.81)
4	Other income	209.29	147.95	134.57	677.27	584.83
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	106.20	867.42	3,812.94	576.37	(2,083.98)
6	Finance costs	-	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	106.20	867.42	3,812.94	576.37	(2,083.98)
8	Exceptional items	-	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	106.20	867.42	3,812.94	576.37	(2,083.98)
10	Tax expense	50.47	-	-	50.47	-
11	Net profit/(loss) from ordinary activities after tax (9-10)	55.73	867.42	3,812.94	525.90	(2,083.98)
12	Extraordinary Item	-	-	-	-	-
13	Net profit/(loss) for the period (11-12)	55.73	867.42	3,812.94	525.90	(2,083.98)
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				15,101.43	14,575.53
16	Basic and diluted earnings per share (of Rs 2 each) [not annualised] See accompanying note to the Financial Results	0.22	3.47	15.25	2.10	(8.34)

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 25 May 2016.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. 'Others' comprise service income pertaining to clinical trials.
- The Company has entered into various distribution and service agreements to promote and distribute certain brands. In line with the agreements, the Company has recognized upfront fees of Rs 3,710 lakhs for the marketing efforts already undertaken by the Company as other operating income during the year ended 31 March 2016.
- AstraZeneca Pharmaceuticals AB, Sweden, the promoter of the Company vide its letter dated 1 March 2014, had proposed voluntary delisting of equity shares from stock exchanges ('Delisting Proposal'). The Board of Directors of the Company at their meeting held on 15 March 2014, had accorded approval for the Delisting Proposal. Further, the Delisting Proposal has been approved by the requisite majority of shareholders of the Company as required under Regulation 8 of SEBI (Delisting of Equity Shares) Regulations, 2009. Securities Exchange Board of India (SEBI) in its Order dated 24 June 2014 has issued directions to Bombay Stock Exchange and National Stock Exchange to closely monitor the entire delisting process of the Company and the Company shall finally purchase shares from the public shareholders in the delisting offer only after seeking approval from Bombay Stock Exchange and National Stock Exchange. The Company has received in-principle approval of National Stock Exchange and Bombay Stock Exchange, for voluntary delisting of equity shares from the said exchanges. A writ petition had been filed by two shareholders of the Company before the Honourable High Court of Judicature at Bombay ("the Court"), seeking inter-alia an order from the Court, restraining the Company and AstraZeneca Pharmaceuticals AB, Sweden ("AZPAB") from implementing the Delisting Proposal. The Court which heard the petition on 8 October 2014 has disposed off the same, with the directions that the Petitioners as well as the Company and AZPAB are at liberty to prefer appeal against SEBI Order dated 24 June 2014, to the Securities Appellate Tribunal (SAT), within six weeks and until the SAT hears and disposes of the Petitioners' appeal, the Company and AZPAB shall not take any further steps in the process of delisting of equity shares of the Company. The SAT was requested to hear and decide the appeals as expeditiously as possible and preferably by 28 February 2015. Further, an appeal has also been filed by two shareholders of the Company before the SAT, Mumbai, against part of SEBI's Order dated 24 June 2014, in relation to Delisting Proposal. The case was posted for hearing on multiple dates during the year ended 31 March 2015. At the hearing held on 5 May 2015, the SAT-posted the matter to be heard on 9 July 2015 which was subsequently rescheduled for hearing on 11 August 2015. In the final hearing held on 11 September 2015, the SAT has disposed off the appeal directing SEBI to complete the investigation within a period of six months from date of its order and pass appropriate order on merits. The SAT has further directed the Company and the Promoter not to proceed with the delisting of equity shares till the completion of investigation and passing of the above mentioned order on merits by SEBI. Also the SAT has directed the Company and the Promoters that if the order passed by SEBI on merits is adverse to the appellants, then the said order shall not be given effect to from the date of passing the said order till it is communicated to the appellants and four weeks thereafter.
- During the previous year ended 31 March 2015, the Company entered into agreements with group companies, namely, AstraZeneca UK, London, AstraZeneca AB, Sweden and IPR Pharmaceuticals Inc. Puerto Rico, towards reimbursement of certain costs incurred for the marketing and promotion of new launch products and support for the distribution of other products supplied by these group companies, in accordance with the arm's length return on revenues. As per the terms of the agreements, in the previous year ended 31 March 2015, the Company billed Rs 2,012.70 lakhs towards reimbursement of certain costs incurred for marketing and promotion of a new launch product which was reduced from the respective expenses head and a sum Rs 4,763.09 lakhs towards support for the distribution of other products supplied by the group companies which was accounted as other operating income. Further, during the current quarter and year ended 31 March 2016, the Company has incurred Rs 1,248.03 lakhs towards certain costs for the marketing and promotion of a new launch product. As the upfront fees received during the year for distribution and service agreements exceeds the expenses incurred towards marketing and promotion of the new launch product, the same have not been billed to the Group companies in the current year.
- The figures for the quarter ended 31 March 2016 and the corresponding quarter ended in the previous year as reported in this financial result is the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also figures upto the third quarter of the relevant financial year were only reviewed and not subjected to audit. The statutory auditors have issued an unqualified audit report. The audit report has been filed with the stock exchange and is also available on the Company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjay Murdeshwar
Managing Director

Bangalore
Dated: 25 May 2016

AstraZeneca Pharma India Limited

Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045

Statement of assets and liabilities

		(Rs in lakhs)	
SI.No.	Particulars	As at 31 March 2016 (Audited)	As at 31 March 2015 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	500.00	500.00
	(b) Reserves and Surplus	15,101.43	14,575.53
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	15,601.43	15,075.53
2	Share application money pending allotment	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	126.69	101.89
	(d) Long-term provisions	-	-
	Sub-total - Non-current liabilities	126.69	101.89
4	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	9,462.84	11,127.16
	(c) Other current liabilities	12,073.41	11,160.01
	(d) Short-term provisions	3,307.73	3,694.68
	Sub-total - Current liabilities	24,843.98	25,981.85
	TOTAL - EQUITY AND LIABILITIES	40,572.10	41,159.27
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	10,366.82	11,319.41
	(b) Non-current investments	0.05	0.05
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	3,316.27	3,455.24
	(e) Other non-current assets	60.55	58.53
	Sub-total - Non-current assets	13,743.69	14,833.23
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	7,672.96	8,613.07
	(c) Trade receivables	8,435.58	4,277.27
	(d) Cash and bank balances	7,683.17	2,508.44
	(e) Short-term loans and advances	2,763.69	10,746.06
	(f) Other current assets	273.01	181.20
	Sub-total - Current assets	26,828.41	26,326.04
	TOTAL - ASSETS	40,572.10	41,159.27

bn

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 31/03/2016 (Audited) ²	3 months ended 31/12/2015 (Unaudited)	3 months ended 31/03/2015 (Audited)	Year ended 31/03/2016 (Audited) ²	Previous year ended 31/03/2015 (Audited)
1	Segment revenue					
	(a) Healthcare	15,438.15	14,319.59	16,718.50	55,402.82	51,614.13
	(b) Others	443.89	138.62	136.53	970.41	92.81
	Net sales/income from operations	15,882.04	14,458.21	16,855.03	56,373.23	51,706.94
2	Segment results					
	Profit/(loss) before tax and interest					
	(a) Healthcare	(113.27)	709.80	3,671.60	(135.16)	(2,721.38)
	(b) Others	10.18	9.67	6.78	34.26	52.57
	Total	(103.09)	719.47	3,678.38	(100.90)	(2,668.81)
	Add: Other income	209.29	147.95	134.57	677.27	584.83
	Add: Exceptional item	-	-	-	-	-
	Less: Interest	-	-	-	-	-
	Total profit/(loss) before tax	106.20	867.42	3,812.95	576.37	(2,083.98)
3	Capital employed					
	(a) Healthcare	6,791.87	5,110.87	11,853.74	6,791.87	11,853.74
	(b) Others	(165.94)	(419.26)	(254.16)	(165.94)	(254.16)
	(c) Unallocated	8,975.50	10,854.09	3,475.95	8,975.50	3,475.95
	Total	15,601.43	15,545.70	15,075.53	15,601.43	15,075.53

Notes :

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 The figures for the quarter ended 31 March 2016 and the corresponding quarter ended in the previous quarter as reported in this financial result is the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year.